The future of pharmacogenetics in Parkinson's disease treatment

PharmacogenomicsVol. 19, No. 3 EditorialThe future of pharmacogenetics in Parkinson's disease treatmentMara H Hutz & Carlos RM RiederMara H Hutz*Author for correspondence: Tel.: +55 51 3308 6720; Fax: +55 51 3308 7311; E-mail Address: mara.hutz@ufrgs.br Departamento de Genética, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, 91501-970, Brazil & Carlos RM Rieder Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, 90035-903, BrazilPublished Online:1 Dec 2017https://doi.org/10.2217/pgs-2017-0180AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: genetic diversityParkinson's diseasepharmacogenomicsReferences1 Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 373, 2055–2066 (2009).Crossref, Medline, CAS, Google Scholar2 Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson's disease. J. Neurol. 249, 138–145 (2002).Crossref, Medline, Google Scholar3 Marras C, Lang A. Parkinson's disease subtypes: lost in translation? J. Neurol. Neurosurg. Psychiatry 84, 409–415 (2013).Crossref, Medline, Google Scholar4 Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 7, 499–504 (2014).Crossref, Google Scholar5 Riedel O, Bitters D, Amann U, Garbe E, Langner I. Estimating the prevalence of Parkinson's disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data. Int. J. Geriatr. Psychiatry 31, 938–943 (2016).Crossref, Medline, CAS, Google Scholar6 Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The incidence of Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology 46, 292–300 (2016).Crossref, Medline, Google Scholar7 Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic reviewand meta-analysis. Mov. Disord. 29, 1583–1590 (2014).Crossref, Medline, Google Scholar8 Cacabelos R. Parkinson's disease: from pathogenesis to pharmacogenomics. Int. J. Mol. Sci. 18(3), pii:E551 (2017).Crossref, Google Scholar9 Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16(3), 448–458 (2001).Crossref, Medline, CAS, Google Scholar10 Sharma JC, Bachmann CG, Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat. Disord. 16(8), 490–497 (2010).Crossref, Medline, CAS, Google Scholar11 Rieck M, Schumacher-Schuh AF, Altmann V et al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. Pharmacogenomics 13, 1701–1710 (2012).Link, CAS, Google Scholar12 Factor SA. Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics 5, 164–180 (2008).Crossref, Medline, CAS, Google Scholar13 Kalinderi K, Fidani L, Katsarou Z, Bostantjopoulou S. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease. 65, 1289–1294 (2011).Crossref, Google Scholar14 Schumacher-Schuh AF, Rieder CR, Hutz MH. Parkinson's disease pharmacogenomics: new findings and perspectives. Pharmacogenomics 15, 1253–1271 (2014).Link, CAS, Google Scholar15 Payami H, Factor SA. Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson's disease. A perspective. Neurotherapeutics 11, 111–116 (2014).Crossref, Medline, CAS, Google Scholar16 Payami H. The emerging science of precision medicine and pharmacogenomics for Parkinson's disease. Mov. Disord. 32, 1139–1146 (2017).Crossref, Medline, Google Scholar17 Hill-Burns EM, Debelius JW, Wissemann WT et al. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Mov. Disord. 32, 739–749 (2017).Crossref, Medline, CAS, Google Scholar18 Bu LL, Yang K, Xiong WX et al. Toward precision medicine in Parkinson's disease. Ann. Transl. Med. 4(2), 26 (2016).Medline, Google Scholar19 von Coelln R, Shulman LM. Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson's disease. Curr. Opin. Neurol. 29, 727–734 (2016).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByPharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study5 November 2020 | Molecular Biology Reports, Vol. 47, No. 11Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives5 November 2018 | Molecular Neurobiology, Vol. 56, No. 7 Vol. 19, No. 3 Follow us on social media for the latest updates Metrics Downloaded 252 times History Received 2 November 2017 Accepted 3 November 2017 Published online 1 December 2017 Published in print February 2018 Information© 2018 Future Medicine LtdKeywordsgenetic diversityParkinson's diseasepharmacogenomicsFinancial & competing interests disclosureMH Hutz and CRM Rieder are funded by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil) and Coordenação de Pessoal de Nývel Superior (CAPES, Brazil). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download